Figure 3From: Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials Mean percentage change in platelet count before and after treatment in Part A. Back to article page